Abstract
Biomarkers are chemical and physiologic parameters that can provide reliable and predictive information about the course and treatment of a given illness. Biomarkers are being increasingly sought after in other medical conditions, and in some instances (eg, breast cancer therapy) are beginning to be incorporated into clinical decision making. There is a confluence of research investigating potential biomarkers for schizophrenia. This article reviews early progress and strategies for evaluating biomarkers, as well as how this approach can advance the treatment of schizophrenia toward personalized medicine.
Copyright © 2012 Elsevier Inc. All rights reserved.
MeSH terms
-
Biomarkers / metabolism*
-
Brain-Derived Neurotrophic Factor / metabolism
-
Carrier Proteins / metabolism
-
Dopamine / metabolism
-
Dysbindin
-
Dystrophin-Associated Proteins
-
Glutamic Acid / metabolism
-
Humans
-
Nerve Tissue Proteins / metabolism
-
Neuregulins / metabolism
-
Precision Medicine
-
Predictive Value of Tests
-
Prognosis
-
Proto-Oncogene Proteins c-akt / metabolism
-
Schizophrenia* / diagnosis
-
Schizophrenia* / metabolism
-
Schizophrenia* / therapy
-
Signal Transduction
-
gamma-Aminobutyric Acid / metabolism
Substances
-
Biomarkers
-
Brain-Derived Neurotrophic Factor
-
Carrier Proteins
-
DTNBP1 protein, human
-
Dysbindin
-
Dystrophin-Associated Proteins
-
Nerve Tissue Proteins
-
Neuregulins
-
Glutamic Acid
-
gamma-Aminobutyric Acid
-
AKT1 protein, human
-
Proto-Oncogene Proteins c-akt
-
Dopamine